Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 T cells and the investigators will determine the safety and therapeutic effects of these cells.

Inclusion Criteria:

CD19 positive leukemia and lymphoma，relapsed and/or refractory：

• survival>12 weeks;
• FEV1, FVC and DLCO ≥50% of expected corrected for hemoglobin;
• LVEF≥50%;
• Creatinine<2.5mg/dl;
• Bilirubin<2.5mg/dl;
• ALT (alanine aminotransferase)/AST (aspartate aminotransferase)<3 x normal;
• At least 7 days after last chemotherapy;
• provide with informed consent.

Exclusion Criteria:

• Active clinically significant CNS dysfunction
• Pregnant or breast-feeding women.
• Uncontrolled active infection including hepatitis B or C.
• HIV positive.
• Use of systemic steroids within 72 hours.
• Allogeneic lymphocyte treatments within recent 6 months.
• Any uncontrolled active medical disorder.